Proposal for fasting insulin and HOMA-IR reference intervals based on an extensive Brazilian laboratory database.

Objective: Fasting insulin and the homeostasis model assessment of insulin resistance (HOMA-IR) index are relatively simple and reliable noninvasive markers of insulin resistance (IR). Given the relevance of correctly diagnosing IR, we emphasize the importance of establishing reliable reference intervals (RIs) for these markers. This study aimed to determine the RIs of fasting insulin and HOMA-IR index in adults living in Rio de Janeiro and, secondarily, to verify potential RI differences between sexes.

[Critical analysis of WHO, IDF and NCEP criteria for metabolic syndrome among patients with type 1 diabetes mellitus].

Objective: To evaluate the frequency of the metabolic syndrome (MS) among adults with type 1 diabetes mellitus (T1DM) according to the International Diabetes Federation (IDF), National Cholesterol Education Program (NCEP) and World Health Organization (WHO) criteria, analyzing each one comparatively. Secondarily we assessed whether MS is associated with microvascular complications, age, diabetes duration and glycemic control.

Methods: This was a cross-sectional study with 101 patients.

Total estradiol, rather than testosterone levels, predicts osteoporosis in aging men.

Objective: To study and establish sex hormone cutoff levels for osteoporosis risk in men over 50 years old.

Methods: Case-control study of 216 men > 50 years, 110 with osteoporosis (O) and 106 with normal bone density (C). We measured estradiol (E2), sex hormone binding globulin (SHBG), total testosterone (TT) and albumin.

Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.

Background: Human growth hormone (hGH) circulates as a mixture of different isoforms. It has been previously reported that the ratio of 20kDa to 20kDa plus 22kDa (%20kDa-hGH) is increased in patients with active acromegaly.

Objectives: To evaluate the GH isoforms (20kDa- and 22kDa-hGH) in acromegalic patients before and after six months of treatment with octreotide LAR, and to compare the results with those in healthy controls.

Risk of late-onset hypogonadism (andropause) in Brazilian men over 50 years of age with osteoporosis: usefulness of screening questionnaires.

Objective: To analyze the relative risk of late-onset hypogonadism in men with osteoporosis and the usefulness of screening questionnaires.

Methods: We correlated the Aging Male's Symptoms (AMS), Androgen Deficiency in Aging Male (ADAM) and International Index of Erectile Function (IIEF-5) questionnaires and the laboratory diagnosis of hypogonadism in 216 men aged 50-84 years (110 with osteoporosis and 106 with normal bone density, paired by age and ethnicity).

Results: Hypogonadism presented in 25% of the osteoporotic and in 12.

[Evaluation of glucose metabolism in acromegalic patients before and after treatment with octreotide LAR].

Aim Of The Study: To evaluate the glucose metabolism in acromegalic patients before and after treatment with octreotide LAR.

Patients And Methods: This was a prospective and longitudinal study involving 30 patients from the acromegaly research outpatient clinic of the Endocrinology unit of the HUCFF/UFRJ. They underwent clinical and laboratorial evaluations, with measurements of growth hormone (GH), insulin-like growth factor type I (IGF-I), insulin, proinsulin, C peptide, glycosylated hemoglobin (HbA1c), IGF binding protein type 1 (IGFBP-1) and glucose, during oral glucose tolerance test (OGTT), before and after six months of treatment with octreotide LAR.

Quality of life in women with microprolactinoma treated with dopamine agonists.

Objectives: To evaluate QOL in women with microprolactinomas treated with dopamine agonists, comparing the patients with normal versus those with elevated prolactin levels, and to identify clinical and biochemical influences on patients' QOL.

Material And Methods: A cross-sectional evaluation was performed in two University referral centers. Fifty women with microprolactinoma answered the SF-36 questionnaire by the time of their clinical evaluation.

Bone density in women with prolactinoma treated with dopamine agonists.

Objectives: (1) to evaluate bone density in women with prolactinoma treated with dopamine agonists and healthy controls, using dual energy x-ray absorptiometry (DXA), (2) to classify the results according to the current International Society for Clinical Densitometry (ISCD) criteria, and (3) to correlate bone density with lean and fat masses, biochemical data and clinical aspects of prolactinomas.

Materials And Methods: A cross-sectional study was performed in two University referral centers. Forty-five premenopausal women with prolactinoma were submitted to DXA and blood analysis (prolactin, estradiol, testosterone, SHBG, calcium, phosphorus, PTH, C-telopeptides of type 1 collagen, and osteocalcin) by the time of their clinical evaluation.

Body fat in nonobese women with prolactinoma treated with dopamine agonists.

Objectives: To evaluate body fat in nonobese women with prolactinoma treated with dopamine agonists, using whole body dual energy X-ray absorptiometry (DXA) and to correlate DXA results with biochemical data and clinical aspects of the prolactinoma.

Design, Patients And Measurements: A cross-sectional study was performed in two University referral centres. Thirty-one nonobese premenopausal women with prolactinoma were subjected to DXA and blood analysis at clinical evaluation.